Russell Investments Group, Ltd. Allakos Inc. Transaction History

Russell Investments Group, Ltd.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$1.0 - $1.45 $4,213 - $6,108	4,213 New	4,213 $4,000
Q3 2023 Nov 13, 2023	SELL	$2.13 - $5.55 $27,400 - $71,395	-12,864 Reduced 99.19%	105 $0
Q1 2023 May 09, 2023	BUY	$4.3 - $8.27 $55,766 - $107,253	12,969 New	12,969 $57,000
Q1 2022 May 05, 2022	BUY	$5.08 - $9.81 $91,119 - $175,961	17,937 Added 200.12%	26,900 $153,000
Q4 2021 Jan 21, 2022	SELL	$8.55 - $111.89 $6,096 - $79,777	-713 Reduced 7.37%	8,963 $86,000
Q3 2021 Nov 08, 2021	SELL	$76.53 - $110.43 $135,534 - $195,571	-1,771 Reduced 15.47%	9,676 $1.02 Million
Q2 2021 Aug 04, 2021	SELL	$85.37 - $114.1 $560,539 - $749,180	-6,566 Reduced 36.45%	11,447 $976,000
Q1 2021 May 10, 2021	SELL	$109.73 - $153.66 $602,856 - $844,208	-5,494 Reduced 23.37%	18,013 $2.07 Million
Q4 2020 Feb 08, 2021	BUY	$79.58 - $152.45 $215,582 - $412,987	2,709 Added 13.03%	23,507 $3.29 Million
Q3 2020 Nov 09, 2020	BUY	$66.43 - $90.99 $1.26 Million - $1.73 Million	19,027 Added 1074.36%	20,798 $1.69 Million
Q2 2020 Aug 05, 2020	BUY	$44.04 - $80.69 $21,183 - $38,811	481 Added 37.29%	1,771 $127,000
Q1 2020 May 06, 2020	BUY	$44.49 - $93.39 $57,392 - $120,473	1,290 New	1,290 $57,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $79.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.